Abstracts tagged "Traps and canakinumab"

Abstract Number: 2379 • 2016 ACR/ARHP Annual Meeting
Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes
Anna Simon¹, Anna Shcherbina², Jordi Anton³, Eldad Ben-Chetrit⁴, Fabrizio De Benedetti⁵, Joost Frenkel⁶, Marco Gattorno⁷, Ryoki Hara⁸, Philip J Hashkes⁹, Michaël Hofer¹⁰, Hal M. Hoffman¹¹, Isabelle Koné-Paut¹², Helen Lachmann¹³, Alberto Martini¹⁴, Seza Ozen¹⁵, Andrew Zeft¹⁶, Antonio Speziale¹⁷, Guido Junge¹⁷ and Jill Gregson¹⁷, ¹General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Clinical immunology Department, Center of Children's Hematology n.a. D. Rogachev, Moscow, Russian Federation, ³Hospital Sant Joan de Déu, Barcelona, Spain, ⁴Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ⁵IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ⁶University Medical Center Utrecht, Utrecht, Netherlands, ⁷Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁸Yokohama City University, Yokohama, Japan, ⁹Pediatrics Rheumatology; Shaare-Zedek Medical Center, Jerusalem, Israel, ¹⁰Pediatric Rheumatology of Western Switzerland, CHUV, University of Lausanne, Lausanne, Switzerland, ¹¹University of California at San Diego, San Diego, CA, ¹²Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹³UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁴Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ¹⁵Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁶Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Open label studies have shown the efficacy of canakinumab (CAN), a fully human and highly specific anti-IL-1β monoclonal antibody, in patients (pts) with Periodic…
Abstract Number: 3205 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Fabrizio De Benedetti¹, Jordi Anton², Eldad Ben-Chetrit³, Inmaculada Calvo⁴, Joost Frenkel⁵, Marco Gattorno⁶, Hal M. Hoffman⁷, Ozgur Kasapcopur⁸, Isabelle Koné-Paut⁹, Helen Lachmann¹⁰, Michel Moutschen¹¹, Seza Ozen¹², Pierre Quartier¹³, Anna Simon¹⁴, Andrew Zeft¹⁵, Karine Lheritier¹⁶, Antonio Speziale¹⁶ and Guido Junge¹⁶, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²Hospital Sant Joan de Déu, Barcelona, Spain, ³Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ⁴Hospital Universitario y Piltecnico La Fe, Valencia, Spain, ⁵University Medical Center Utrecht, Utrecht, Netherlands, ⁶Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁷University of California at San Diego, San Diego, CA, ⁸Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁹Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹⁰UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹¹C.H.U. Sart-Tilman, Liege, Belgium, ¹²Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹³Hôpital Necker-Enfants Malades, Paris, France, ¹⁴General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁵Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Periodic fever syndromes (PFS) are rare auto-inflammatory conditions that include, among others, cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…
Abstract Number: 938 • 2015 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF Receptor-Associated Periodic Syndrome
Marco Gattorno¹, Marco Cattalini², L. Obici³, Roberto Barcellona⁴, Antonio Speziale⁵, Yolandi Joubert⁵, Guido Junge⁵ and Helen Lachmann⁶, ¹Pediatric Rheumatology, G. Gaslini Institute, Genova, Italy, ²Pediatric Clinic, University of Brescia, Brescia, Italy, ³Amyloid Centre, Policlinico S. Matteo, Pavia, Italy, ⁴Hospital of Sciacca, Sciacca, Italy, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom
Background/Purpose: Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare, dominantly inherited periodic fever syndrome characterized by recurrent attacks of fever associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].